NNG-TMAB (Trastuzumab)

Trastuzumab · Nanogen Pharmaceutical Biotechnology Joint Stock Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NNG-TMAB (Trastuzumab), covering 2023-02-27 to 2023-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients [Phase 3]

See pricing